Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G Pharma Sale Could Bring $1 Billion To Feed Consumer Business

This article was originally published in The Tan Sheet

Executive Summary

A sale of Procter & Gamble's pharma business could fetch about $1 billion, according to an estimate by one analyst. That represents cash P&G could reinvest in its core business areas, beauty and consumer health care, at a time when the recession is impacting growth and the credit crisis is forcing some retailers to cut inventories to conserve cash

You may also be interested in...



P&G Kisses Pharma Biz Goodbye In $3.1B Deal With Warner Chilcott

Warner Chilcott's $3.1 billion acquisition of Proctor & Gamble's pharmaceuticals business on Aug. 24 significantly bolsters the Irish drug maker's sales force and adds to its already lucrative women's health portfolio with the addition of Asacol HD and Actonel,while freeing P&G to focus on consumer health

P&G Kisses Pharma Biz Goodbye In $3.1B Deal With Warner Chilcott

Warner Chilcott's $3.1 billion acquisition of Proctor & Gamble's pharmaceuticals business on Aug. 24 significantly bolsters the Irish drug maker's sales force and adds to its already lucrative women's health portfolio with the addition of Asacol HD and Actonel,while freeing P&G to focus on consumer health

P&G Kisses Pharma Business Goodbye In $3.1 Billion Deal With Warner Chilcott

Ireland-based Warner Chilcott has a "double tax haven," making the P&G deal one with fairly low financial risks, Wall Street analysts say.

Related Content

Topics

UsernamePublicRestriction

Register

PS102618

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel